StimCardio Medical has announced the closing of its oversubscribed US$30 million Series A financing led by John Slump’s family office, Metis Medtech, with participation from Catalyst Health Ventures, multiple corporate strategic investors, and other new and existing investors.
The financing is expected to fund StimCardio through its planned NeuroPulse 2 pivotal study as well as the preparation for a de-novo submission to the US Food and Drug Administration (FDA). NeuroPulse 2—StimCardio states—is a major, multicentre pivotal trial designed to evaluate whether adding wearable neuromodulation to catheter ablation improves clinical outcomes compared with ablation alone in atrial fibrillation (AF) patients.
“Our vision is to establish non-invasive neuromodulation as a new therapeutic category in cardiac electrophysiology,” said Amir Soltanianzadeh, chief executive officer (CEO) of StimCardio. “This financing brings together investors with deep expertise in cardiac device innovation and provides the resources to deliver a first-of-its-kind, multicentre pivotal study. With encouraging clinical evidence to date and a growing research programme, we see an opportunity to extend treatment beyond the procedure room and improve outcomes for the millions of people living with AF.”
“StimCardio is pioneering innovative technology positioned to disrupt the cardiac electrophysiology arena,” added John Slump, CEO and founder of Metis MedTech, and a StimCardio board member. “Despite decades of advances in catheter ablation procedures, AF recurrence remains a significant unmet clinical challenge. StimCardio has an entirely different approach with a non-invasive wearable that we believe will redefine the treatment paradigm. Our decision to invest reflects our strong conviction in this impressive team, disruptive technology, and growing market.”
StimCardio’s lead investigational product, Rhyvive, is a wrist-worn therapeutic wearable designed to deliver personalised, non-invasive median nerve stimulation (MNS) through a closed-loop system that integrates physiological sensing and neuromodulation. Developed as an adjunct to catheter ablation, Rhyvive is intended to extend treatment beyond the procedure and into the patient’s home by modulating autonomic nervous system pathways with the goal of reducing recurrent atrial arrhythmias like AF.
“Catalyst Health Ventures invests early in paradigm-shifting technologies with the potential to transform patient care,” commented Joshua Phillips, managing partner of Catalyst Health Ventures and a StimCardio board member. “StimCardio’s differentiated therapeutic approach targets a significant unmet clinical need affecting a large patient population. Supported by encouraging early clinical evidence, the technology has the potential to reduce AF recurrence following catheter ablation.”
This financing follows the presentation of StimCardio’s NeuroPulse 1 pilot study as a late-breaking clinical trial at HRX Live 2026 (18–20 September, Atlanta, USA) and its peer-reviewed publication in Heart Rhythm. The randomised, double-blind, sham-controlled study demonstrated a statistically significant reduction in recurrent atrial arrhythmia events post-ablation with active MNS stimulation compared with the sham treatment group.
